Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck

Table 1 Overview of the results of overall survival and progression-free survival efficacy of immunotherapy based-consolidation studies (PACIFIC, LUN 14-179) and historic attempts to improve overall survival in stage III non-small cell lung cancer (PROCLAIM and RTOG 0617)

Endpoint	Study and treatment
	PACIFIC durvalumab	PACIFIC placebo	LUN 14-179 pembrolizumab	PROCLAIM pemetrexed	RTOG 0617 (60 Gy RT)	RTOG 0617 cetuximab
Median follow-up	33.3 mo	33.3 mo	18.6 mo	22.2 mo	22.9 mo	21.3 mo
OS
Median	NR	29.1 mo	22.4 mo	26.8 mo	28.7 mo	25 mo
12-mo	83.1%	74.6%	74.7%	76%	80%	76.2%
24-mo	66.3%	55.3%		52%	57.6%	52.3%
36-mo	57%	43.5%		40%
PFS
Median	17.2 mo	5.6 mo	17 mo	11.4 mo	11.8 mo	10.8 mo
12-mo	55.9%	35.3%	60.2%		49.2%	44.3%
24-mo			44.6%		29.1%	24.2%

OS: Overall survival; PFS: Progression-free survival; RT: Radiotherapy.

Table 2 Treatment-related events reported in ≥ 11% of patients in PACIFIC study arms and their rates in LUN 14-179 study¹

Event	Treatment arm and study
	Durvalumab in PACIFIC, n = 475		Placebo in PACIFIC, n = 234		Pembrolizumab in LUN 14-179
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
Any event	96.8%	30.5%	94.9%	26.1%
Cough	35.2%	0.4%	25.2%	0.4%	25.8%	1.1%
Fatigue	24%	0.2%	20.5%	1.3%	46.2%	4.3%
Dyspnea	22.3%	1.5%	23.9%	2.6%	21.5%	5.4%
Radiation pneumonitis	20.2%	1.5%	15.8%	0.4%
Diarrhea	18.5%	0.6%	19.7%	1.3%	15.1%	4.3%
Pyrexia	15.2%	0.2%	9.4%	0%
Nausea	14.3%	0%	13.2%	0%	15.1%	1.1%
Anorexia	14.3%	0.2%	12.8%	0.9%	17.2%	1.1%
Pneumonia	13.3%	4.4%	7.7%	3.8%
Pneumonitis	12.6%	1.9%	7.7%	1.7%	17.2%1	5.4%
Arthralgia	12.4%	0%	5.1%	0%	15.1%	1.1%
Pruritus	12.4%	0%	5.1%	0%	10.8%	0%
Rash	12.2%	0.2%	7.7%	0%	12.9%	1.1%
Constipation	11.8%	0.2%	8.5%	0%
Hypothyroidism	11.6%	0.2%	1.7%	0%	7.5%	0%

¹Grade ≥ 2.